期刊
ONCOTARGETS AND THERAPY
卷 14, 期 -, 页码 3739-3744出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S313896
关键词
KIF5B-EGFR; EGFR fusion; next-generation sequencing; afatinib; non-small cell lung cancer
资金
- National Nature Science Foundation [82060577, 82060547]
EGFR fusions are rare genomic events in NSCLC with no standard treatment options, but TKIs have shown promising results in patients with rare fusions like KIF5B-EGFR, leading to partial responses and extended PFS. Utilizing NGS for the identification of uncommon EGFR mutations in NSCLC patients is crucial for personalized treatment strategies.
Epidermal growth factor receptor (EGFR) fusions are rare genomic events in nonsmall-cell lung cancer (NSCLC). With advances in detection technology, some uncommon genomic mutation events, including EGFR fusions, have been detected. There are no standard treatment options for NSCLC patients harboring EGFR fusion. Herein, we report a case of KIF5B-EGFR fusion in NSCLC responding to tyrosine kinase inhibitors (TKIs). A 50-year-old male underwent left upper lobectomy followed by adjuvant chemotherapy for pathological stage IA3 lung adenocarcinoma. The tumor tissue was subjected to next-generation sequencing (NGS) and showed a KIF5B-EGFR fusion. When cancer recurrence occurred thirteen months later, the patient received afatinib (40 mg qd) as second-line treatment, and a partial response was observed, which resulted in an 11-month progression-free survival (PFS). This case provides valuable information on the response to afatinib in an NSCLC patient with a novel KIF5B-EGFR fusion. The NGS assay provides a powerful tool for identifying rare or atypical EGFR gene mutations in patients with NSCLC, which should be encouraged in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据